Enanta Pharmaceuticals Presenting Preclinical Data for Its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV) Programs at the 12th International RSV Symposium
Enanta Pharmaceuticals Presenting Preclinical Data for Its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV) Programs at the 12th International RSV Symposium
Enanta製藥公司在第12屆呼吸道合胞病毒(RSV)國際研討會上介紹其呼吸道合胞病毒(RSV)和人類偏肺病毒(HMPV)計劃的臨牀前數據
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new preclinical data related to its RSV program, as well as new virology methods used for its RSV and hMPV programs, will be presented during the 12th International RSV Symposium at ICC Belfast in Northern Ireland, United Kingdom. An oral presentation and poster highlight the preclinical characteristics and the in vivo efficacy of EDP-323, a novel non-nucleoside RSV L-inhibitor. Additional posters characterize a 3D culture model for studying RSV, as well as outline methods for improved...
亞洲網加利福尼亞州聖何塞10月24日電埃南塔製藥公司(納斯達克市場代碼:ENTA)是一家致力於開發治療病毒感染和肝病的小分子藥物的臨牀階段生物技術公司。該公司今天宣佈,與其呼吸道合胞病毒計劃相關的新的...
登入免費觀看全文
登入/註冊